New data shows promise for Merck KGaA's oral multiple sclerosis drug cladribine

A new analysis of data from a clinical trial of Merck KGaA's oral drug cladribine has underscored its potential as a treatment for multiple sclerosis, say researchers.

The fresh finding from the Phase III trial -- headline results of which were first presented in April -- showed a short course of cladribine tablets significantly increased the proportion of patients without disease activity after two years.

Commenting on the study, Helen Yates, Multiple Sclerosis Resource Centre chief executive said: 'The work that is being undertaken on oral therapies is very important to people with MS. Removing the need for weekly or even daily injections is a goal that is understandably significant. Cladribine seems to be producing good results in trials and it is hoped that this drug makes the final part of its journey to market and becomes available to people with MS for whom it is appropriate!"